RxDoctor Payments Data

Angeline Derham, MD

Ophthalmology · Austin, TXNPI 1255795217

Payments from drug & device makers

$4,183in general payments, 2019–2025

Across 125 payments — averaging $33.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$717
  • Rxsight Inc$450
  • Bausch & Lomb Americas Inc.$391
  • Johnson & Johnson Surgical Vision, Inc.$349
  • Amgen$213
  • plus $866 from 13 others

What the payments were for

  • Food & beverage$4,11998%
  • Other$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,183 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$108,690
Medicare patients
492
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine134$109,797
Cyclosporine82$30,665
XiidraLifitegrast45$29,915
MieboPerfluorohexyloctane/Pf17$13,611
LumiganBimatoprost26$11,928
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$4,317
Prednisolone Acetate100$3,769
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat92$1,692
Latanoprost142$1,687
Doxycycline Monohydrate60$1,124
Brimonidine Tartrate34$1,027
Ketorolac Tromethamine20$724
MoxifloxacinMoxifloxacin Hcl23$543
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$529
Cromolyn Sodium31$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$1,198$121,725160 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$391$43,52662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →